Previous reports demonstrated that LINC00426 promotes LUAD progression and doxorubicin resistance in OSA, suggesting a potential oncogenic role of LINC00426 in these cancers (Wang L. et al., 2020; Du, 2020). This evidence concerns the gene LINC00426 and cancer.